BioLineRx Ltd. (BLRX)
2.80
-0.01
(-0.36%)
USD |
NASDAQ |
Aug 24, 16:00
2.80
0.00 (0.00%)
After-Hours: 20:00
BioLineRx Enterprise Value : 8.106M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 8.106M |
| August 20, 2026 | 7.889M |
| August 19, 2026 | 8.628M |
| August 18, 2026 | 8.280M |
| August 17, 2026 | 7.367M |
| August 14, 2026 | 7.889M |
| August 13, 2026 | 7.709M |
| August 12, 2026 | 7.584M |
| August 11, 2026 | 7.954M |
| August 10, 2026 | 7.680M |
| August 07, 2026 | 7.671M |
| August 06, 2026 | 8.019M |
| August 05, 2026 | 7.702M |
| August 04, 2026 | 7.889M |
| August 03, 2026 | 7.441M |
| July 31, 2026 | 8.150M |
| July 30, 2026 | 7.628M |
| July 29, 2026 | 7.845M |
| July 28, 2026 | 8.106M |
| July 27, 2026 | 8.137M |
| July 24, 2026 | 8.150M |
| July 23, 2026 | 8.324M |
| July 22, 2026 | 8.273M |
| July 21, 2026 | 8.585M |
| July 20, 2026 | 8.193M |
| Date | Value |
|---|---|
| July 17, 2026 | 8.498M |
| July 16, 2026 | 8.846M |
| July 15, 2026 | 8.542M |
| July 14, 2026 | 9.151M |
| July 13, 2026 | 9.368M |
| July 10, 2026 | 9.325M |
| July 09, 2026 | 9.064M |
| July 08, 2026 | 8.977M |
| July 07, 2026 | 9.616M |
| July 06, 2026 | 9.616M |
| July 02, 2026 | 10.17M |
| July 01, 2026 | 9.673M |
| June 30, 2026 | 9.455M |
| June 29, 2026 | 9.368M |
| June 26, 2026 | 9.651M |
| June 25, 2026 | 9.434M |
| June 24, 2026 | 10.54M |
| June 23, 2026 | 10.06M |
| June 22, 2026 | 9.977M |
| June 18, 2026 | 9.629M |
| June 17, 2026 | 9.020M |
| June 16, 2026 | 9.151M |
| June 15, 2026 | 9.999M |
| June 12, 2026 | 10.54M |
| June 11, 2026 | 10.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 417.07M |
| Can-Fite BioPharma Ltd. | -4.518M |
| Galmed Pharmaceuticals Ltd. | -12.02M |
| Revium Recovery, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.581M |
| Revenue (Quarterly) | 0.4757M |
| Total Expenses (Quarterly) | 3.057M |
| EPS Diluted (Quarterly) | -0.5804 |
| Gross Profit Margin (Quarterly) | 61.64% |
| Profit Margin (Quarterly) | -542.6% |
| Earnings Yield | -76.46% |
| Normalized Earnings Yield | -76.69 |